Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol

OBJECTIVE: Arformoterol is the (R,R)-enantiomer of formoterol. Preclinical studies suggest that it is a stronger bronchodilator than the racemic (R,R/S,S)-formoterol; however, its potential clinical advantages have not been demonstrated. This study compared the length of stay (LOS), 30-day readmissi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganapathy, Vaidyanathan, Stensland, Michael D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490469/
https://www.ncbi.nlm.nih.gov/pubmed/28694692
http://dx.doi.org/10.2147/COPD.S134145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490469/
https://www.ncbi.nlm.nih.gov/pubmed/28694692
http://dx.doi.org/10.2147/COPD.S134145

Ejemplares similares